article Open AccessTop 1% cited

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

Ophthalmology · 2016 · Vol. 123(6) · pp. 1351–1359

John A. Wells✉(Palmetto Retina Center)Adam R. Glassman(Jaeb Center for Health Research)Allison R. Ayala(Jaeb Center for Health Research)Lee M. Jampol(Northwestern University)Neil M. Bressler(Johns Hopkins University)Susan B. Bressler(Johns Hopkins University)Alexander J. Brucker(Penn Presbyterian Medical Center)Frederick L. Ferris(National Eye Institute)G. Robert Hampton(Retina Vitreous Associates of Florida)Chirag JhaveriMichele Melia(Jaeb Center for Health Research)Roy W. Beck(Jaeb Center for Health Research)

View via DOI Publisher page

Retinal Diseases and Treatments Retinal Imaging and Analysis Ocular Diseases and Behçet’s SyndromeAfliberceptRanibizumabMedicineBevacizumabOphthalmologyVisual acuityRegimenDiabetic macular edemaRandomizationDiabetic retinopathy

MeSH terms

BevacizumabRanibizumabAgedCombined Modality TherapyDiabetic RetinopathyFemaleFollow-Up StudiesHumansMacular EdemaMaleMiddle AgedRecombinant Fusion ProteinsVisual AcuityTreatment OutcomeLaser Coagulation

Citations

1,008

FWCI

100.08

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Diabetic Retinopathy: Pathophysiology and Treatments